Gilead's top late-stage drug selonsertib, for patients with compensated cirrhosis due to nonalcoholic steatohepatitis (NASH), has failed a phase 3 trial. The drug, an apoptosis signal-regulating ...

Novartis has joined with Allergan in a bid to get ahead in the race to get a drug approved to treat the fatty liver disease, non-alcoholic steatohepatitis (NASH). The Swiss pharma said it is to ...

Graham Nash has always been one of the most dependable members of CSN, but he had little patience for when some people dragged their feet.

We recently published a list of 10 Best Performing Growth Stocks in 2025 In this article, we are going to take a look at ...

Medically reviewed by Qin Rao, MD Metabolic dysfunction-associated steatohepatitis (MASH)—previously known as nonalcoholic ...

Identify the warning signs of hepatitis before they become serious. From subtle fatigue to more obvious symptoms, recognizing liver inflammation early can save.

Shilpa Medicare Limited (BSE: 530549) (NSE: SHILPAMED), a leading API and formulation manufacturer, announces that the ...

Shares Expected to Begin Trading on Split-Adjusted Basis on March 18, 2025MORRISTOWN, N.J., March 14, 2025 (GLOBE NEWSWIRE) -- Hepion ...

Shares of Viking Therapeutics VKTX gained more than 11% on Wednesday after the company announced that it had signed a broad ...

The liver is essential for digestion, metabolism, detoxification, and fluid regulation. While alcohol abuse is a known cause ...

Three more Milwaukee schools are temporarily closing because of lead hazards inside of the buildings. In a letter sent to MPS ...

Equities research analysts at HC Wainwright reduced their Q1 2025 earnings per share estimates for shares of Aligos Therapeutics in a report issued on Tuesday, March 11th. HC Wainwright analyst E.